Pascal Biosciences CEO interview on Canada Pot Talks 107.7 Pulse FM (minute 46)
Listen to an interview with CEO Patrick Gray on Canada Pot Talks. Canada Pot Talks - November 10th 2018
Read MoreCFN's exclusive Interview with Pascal Biosciences
CEO Patrick Gray sat down with CFN Media for an exclusive interview. Read the full interview here.
Read MorePascal Biosciences Announces Optimization of Cannabinoid-Derived Drug Candidates to Kill Glioblastoma Cells
VANCOUVER, British Columbia and SEATTLE, Nov. 05, 2018 (GLOBE NEWSWIRE) -- Pascal Biosciences Inc. (TSX.V:PAS)(“Pascal” or the “Company”), a drug discovery and development company, today announced the peer reviewed publication and upcoming presentation of their recently licensed cannabinoid-derived drug program for…
Read MorePascal Biosciences and the University of Washington Enter Into Exclusive License Agreement to Develop Cannabinoid-based Medicine for Cancer
Program Developed in Lab of Renowned Cannabis Researcher Dr. Nephi Stella Lead Candidate for Glioblastoma to Begin Clinical Testing in 2019 VANCOUVER, B.C. and SEATTLE, Oct. 30, 2018 (GLOBE NEWSWIRE) -- Pascal Biosciences Inc. (TSX.V:PAS) (“Pascal” or the “Company”), a…
Read MorePascal Biosciences appoints Julie M. Eastland, accomplished financial executive, to Board of Directors
VANCOUVER, British Columbia, July 16, 2018 (GLOBE NEWSWIRE) -- Pascal Biosciences Inc. (TSX.V:PAS) (“Pascal” or the “Company”), a drug discovery and development company, today announced the appointment of Julie M. Eastland to the Board of Directors, effective immediately. Ms. Eastland is a…
Read MorePascal Biosciences Receives DEA Schedule I License for Cannabinoid Development and Renews UBC Collaboration
VANCOUVER, British Columbia, June 18, 2018 (GLOBE NEWSWIRE) -- Pascal Biosciences Inc. (TSX-V:PAS) (Pascal), is pleased to announce significant progress in its cannabinoid based research and development program with the University of British Columbia (UBC). Pascal has been licensed by…
Read MorePascal Biosciences Identifies Molecules in Cannabis That Stimulate the Immune System to Destroy Tumor Cells
VANCOUVER, BRITISH COLUMBIA and SEATTLE, WASHINGTON, February 21, 2018 - Pascal Biosciences Inc. (TSX.V:PAS) (“Pascal” or the “Company”) today announced the Company has discovered certain cannabinoids that enhance the immunogenicity of tumor cells, rendering them more susceptible to recognition by the immune system.…
Read MorePascal Announces the Appointment of a New Director, Dr. Graeme I. Bell
VANCOUVER, B.C., Dec. 05, 2017 (GLOBE NEWSWIRE) -- Pascal Biosciences, Inc. ("Pascal" or the "Company") (TSX VENTURE:PAS), a biotechnology company that specializes in cancer drug discovery and development, today announced the appointment of Dr. Graeme I. Bell to its Board of Directors.…
Read MorePascal Biosciences Acquires Technology to Treat Leukemia from the University of New Mexico
VANCOUVER, BRITISH COLUMBIA, September 11, 2017 - Pascal Biosciences Inc. (TSX.V:PAS) (“Pascal” or the “Company”), a drug discovery and development company, today announced that the Company has executed an exclusive, worldwide license option agreement with STC.UNM (“STC”), the University of New…
Read MorePascal Biosciences Creates Development Science Lab In Seattle, WA
VANCOUVER, BRITISH COLUMBIA, May 9, 2017 --Pascal Biosciences Inc. (formerly bioMmune Technologies Inc.) (TSX.V/PAS) (“Pascal” or the “Company”), a biotechnology company that specializes in drug discovery and development, is pleased to announce that the Company has created a new, wholly…
Read More